BALVERSA®

(erdafitinib)

BALVERSA® (erdafitinib)

Pivotal clinical trial publications

BLC-3001 (THOR)

Loriot Y, Matsubara N, Park SH, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389:1961-1971.

Loriot Y, Matsubara N, Park SH, et al. Supplement for: Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389:1961-1971.

Loriot Y, Matsubara N, Park SH, et al. Protocol for: Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389:1961-1971.

BLC-2001

Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338-348.

Loriot Y, Necchi A, Park SH, et al. Supplementary appendix: Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338-348.

Loriot Y, Necchi A, Park SH, et al. Protocol for: Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338-348.

Siefker-Radtke AO, Necchi A, Park SH, et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. [published online ahead of print January 11, 2022]. Lancet Oncol. 2022. doi: 10.1016/S1470-2045(21)00660-4.

Plain language summaries of pivotal clinical trials

BLC-2001

Loriot Y, O'Hagan A, Siefker-Radtke AO. Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up. Future Oncol. 2023 Nov 2. doi: 10.2217/fon-2023-0596.

Medical Inquiries

Connect With My Medical Science Liaison

Chat Live

Available Monday - Friday 9AM - 4:30PM ET

Call Me Now

Available Monday - Friday 9AM - 7:30PM ET

Email Your Inquiry

Call 1-800-JANSSEN

Available Monday - Friday 9AM - 8PM ET

Live Video

Available Monday - Friday 9AM - 4:30PM ET